DOCSLIB.ORG

Photosensitizing Medication List Medication Photosensitizing Amitriptyline Light

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

chapter two tanning fact book 2008/2009 Photosensitizing Medication List MANY MEDICATIONS, TOPICAL SOLUTIONS AND EVEN SOME FOODS CAN CAUSE THE SKIN TO BURN OR BREAK OUT IN A RASH WHEN EXPOSED TO ULTRAVIOLET LIGHT. THE CONSEQUENCES CAN RANGE FROM ITCHINESS TO AN UNCOMFORTABLE RASH AND BURNS. IT IS CRITICAL THAT EVERY SALON OWNER POST A CHART OF PHOTOSENSITIVE MEDICATIONS AND AGENTS IN A CONSPICUOUS LOCATION. IF A CLIENT IS TAKING A MEDICATION THAT ISN’T LISTED, HE OR SHE SHOULD CONSULT WITH A PHYSICIAN OR PHARMACIST BEFORE BEING EXPOSED TO ULTRAVIOLET LIGHT—INDOORS OR OUTDOORS. The most common photosensitizing materials are listed on the • Brand names of products should be considered only as examples; following pages. This is not a list of every material that could have they do NOT represent all names under which the generic product photosensitizing effects. Before using the list, you should be aware may be sold. of the following: The following list was prepared by Jerome I. Levine, M.S., R.Ph., of • NOT all individuals who use or take these medications will experience the U.S. Food and Drug Administration. The list was published under the a photosensitive reaction. Also, an individual who experiences title “Medications That Increase Sensitivity To Light: A 1990 Listing.” a photosensitive reaction on one occasion will NOT necessarily The FDA has confirmed this list to be the most recent. The mention experience it again or every time. of commercial products, their sources or their use in connection with • A medication will NOT cause the same degree of skin reaction in material reported herein is not to be construed as either an actual or all individuals. implied endorsement of such products by the Department of Health and Human Services. Cromolyn Intal Inhaler Antiasthmatic Cyclobenzaprine Flexeril Anti-skeletal, Muscle spasms Reported Photosensitizing Medications Cyproheptadine Periactin Antihistamine, Antiserotonergic Generic Name Brand Name Therapeutic Class Dacarbazine DTIC-Dome Anti-Hodgkin’s disease, Antimetabolite Acetazolamide Diamox Anticonvulsant, Antiglaucoma diuretic Danazol Danocrine Gonadotropin inhibitor Amiloride + Hydrochlorothizide Moduretic Antihypertensive, Thiazide diuretic Demeclocycline Declomycin Antibiotic Amiodarone Cordarone (15%) Antiarrhythmic Desipramine Norpramin Antidepressant (tricyclic) Amitriptyline Elavil Antidepressant (tricyclic) Desipramine Pertofrane Antidepressant (tricyclic) Amitriptyline Endep Antidepressant (tricyclic) Dexchlorpheniramine Polaramine Antihistamine Amoxapine Asendin (<1%) Antidepressant (tricyclic) Diclofenac Voltaren (<1%) NSAID,* Antiarthritic Astemizole Hismanal Antihistamine Diflunisal Dolobid (<1%) NSAID,* Antiarthritic Atenolol + Chlorthalidone Tenoretic Beta-adrenergic blocker, Thiazide Diltiazem Cardizem (<1%) Antianginal, Antihypertensive, Calcium diuretic channel blocker Auranofin Ridaura Antiarthritic, Gold compound Diphenhydramine Benadryl Antihistamine Azatadine Optimine Antihistamine Diphenylpyraline Hispril Spansule Antihistamine Azatidine + Pseudoephedrine Trinalin Repetabs Antihistamine, Decongestant Doxepin Sinequan Antidepressant (tricyclic) Bendroflumethiazide Naturetin Antihypertensive, Thiazide diuretic Doxycycline Vibramycin Antibiotic Benzthiazide Exna Antihypertensive, Thiazide diuretic Doxycycline Hyclate Doryx Antibiotic Bromodiphenhydramine Ambenyl Antihistamine Enalapril Vasotec Antihypertensive Brompheniramine Dimetane Antihistamine Enalapril + Hydrochlorothiazide Vaseretic Antihypertensive, Thiazide diuretic Captopril Capoten Antihypertensive Erythromycin Ethylsuccinate + Sulfisoxazole Pediazole Antibiotic Captopril + Hydrochlorothiazide Capozide Antihypertensive, Thiazide diuretic Estrogens Contraceptive, oral Female sex hormone Carbamazepine Tegretol Analgesic, Anticonvulsant Estrogens Estrogens Female sex hormone Chlordiazepoxide + Amitriptyline Limbitrol Antidepressant (tricyclic), Tranquilizer Ethionamide Trecator-SC Anti-infective, Antituberculosis Chlorothiazide Diuril Antihypertensive, Thiazide diuretic Etretinate Tegison Antipsoriatic Chlorpheniramine Chlorpheniramine Antihistamine Floxuridine FUDR Injectable Antimetabolite, Antineoplastic Chlorpheniramin + D-Pseudoephedrine Deconamine Antihistamine, Decongestant Flucytosine Ancobon Antifungal Chlorpheniramine + Phenylpropanolamine Ru-Tuss II Antihistamine, Decongestant Fluorouracil Adrucil Antineoplastic Chlorpromazine Thorazine Antiemetic, Tranquilizer Fluorouracil Efudex Antineoplastic Chlorpropamide Diabinese Antidiabetic (oral), Sulfonylurea Fluorouracil Fluorouracil Antineoplastic Chlorprothixene Taractan Antiemetic, Tranquilizer Fluphenazine Prolixin Antipsychotic, Tranquilizer Chlorthalidone Hygroton Antihypertensive, Thiazide diuretic Fluphenazine Permitil Antipsychotic, Tranquilizer Chlorthalidone Thalitone Antihypertensive, Thiazide diuretic Flurbiprofen Ansaid NSAID,* Antiarthritic Chlorthalidone + Reserpine Demi-Regroton Antihypertensive, Thiazide diuretic Flutamide Eulexin Antimetastatic (prostatic carcinoma) Chlorthalidone + Reserpine Regroton Antihypertensive, Thiazide diuretic Furosemide Lasix Antihypertensive, Diuretic Ciprofloxacin Cipro (<1%) Anti-infective Gentamicin Garamycin Antibiotic Clemastine Tavist Antihistamine Glipizide Glucotrol Antidiabetic (oral), Sulfonylurea Clofazime Lamprene (<1%) Antibacterial, Antileprosy agent Glyburide Diabeta Antidiabetic (oral), Sulfonylurea Clonidine Chlorthalidone + Combipres Antihypertensive, Thiazide diuretic Glyburide Micronase Antidiabetic (oral), Sulfonylurea Coal Tar Estar Gel Antipsoriatic, Eczema Gold Salts (compounds) Solganal Antiarthritic, Gold compound Coal Tar Balnetar Antipsoriatic, Eczema Gold Sodium Thiomalate Myochrysine Antiarthritic, Gold compound Contraceptive, oral Estrogen Birth control pill, Female sex hormone Griseofulvin Fulvicin U/F Antibiotic, Antifungal looking fit * Non-steroidal anti-inflammatory drug lookingfit.com 23 CH2_LFFB_3_15_08_P17-40.indd 23 2/19/2008 5:25:06 PM chapter two Generic Name Brand Name Therapeutic Class Sulfadoxine + Pyrimethamine Fansidar Antimalarial, Antiprotozoal Griseofulvin Ultramicrosize Grisactin Ultra Antibiotic, Antifungal Sulfamethizole + Phenazopyridine Thiosulfil-A Urinary analgesic, Antibiotic Guanethidine + Hydrochlorothiazide Esimil Antihypertensive, Thiazide diuretic Sulfamethoxazole Gantanol Antibiotic Haloperidol Haldol Antipsychotic, Tranquilizer Sulfamethoxazole + Phenazopyridine Azo Gantanol Antibiotic, Urinary analgesic Hexachlorophene Phisohex Antibacterial Sulfapyridine (Generic only) Dermatitis herpetiformis suppressant Hydralazine + Hydrochlorothiazide Apresazide Antihypertensive, Thiazide diuretic Sulfasalazine Azulfidine Bowel anti-inflammatory Hydralazine Apresoline-Esidrix Antihypertensive, Thiazide diuretic Sulfinpyrazone Anturane Antigout agent, Antihyperuricemic Hydrochlorothiazide Esidrix Antihypertensive, Thiazide diuretic Sulfasoxazole Gantrisin Antibiotic Hydrochlorothiazide Hydrodiuril Antihypertensive, Thiazide diuretic Sulfasoxazole + Phenazopyridine Azo Gantrisin Antibiotic, Urinary analgesic Hydrochlorothiazide Oretic Antihypertensive, Thiazide diuretic Sulfone Dapsone Antileprosy, Antimalarial Hydrochlorothiazide Oreticyl Antihypertensive, Thiazide diuretic Sunlindac Clinoril (<1%) NSAID,* Antiarthritic Hydrochlorothiazide + Triamterene Dyazide Antihypertensive, Thiazide diuretic Terfenadine Seldane Antihistamine Hydrochlorothiazide Maxzide Antihypertensive, Thiazide diuretic Tetracycline Achromycin Antibiotic Hydroflumethiazide Diucardin Antihypertensive, Thiazide diuretic “ ” Sumycin Antibiotic Hydroflumethiazide Saluron Antihypertensive, Thiazide diuretic Thioridazine Mellaril Antipsychotic, Tranquilizer Hydroflumethiazide + Reserpine Salutensin/ Thiothixene Navane Antipsychotic, Tranquilizer Salutensin-Demi Antihypertensive, Thiazide diuretic Timolol + Hydrochlorothiazide Timolide Beta-adrenergic blocker, Ibuprofen Advil (<1%) NSAID,* Antiarthritic Thiazide diuretic Ibuprofen Motrin (<1%) NSAID,* Antiarthritic Tolazamide Tolinase Antidiabetic (oral), Sulfonylurea Imipramine Tofranil Antidepressant (tricyclic) Tolbutamide Orinase Antidiabetic (oral), Sulfonylurea Indapamide Lozol Antihypertensive, Diuretic Tretinoin Retin-A Antiacne (topical) Interferon ALFA-2B Intron A (<1%) Antiviral agent Triamterene Dyrenium Antihypertensive Diuretic Isocarboxazid Marplan Antidepressant, MAO inhibitor Trifluoperazine Stelazine Antipsychotic, Tranquilizer Isotretinoin Accutane Antiacne Triflupromazine Vesprin Antiemetic, Antipsychotic Ketoprofen Orudis (<1%) NSAID,* Antiarthritic Trimeprazine Temaril Antipsychotic, Tranquilizer Labetalol Normodyne Antihypertensive, Beta- and Trimethoprim Trimpex Antibiotic alpha-adrenergic blocker Trimethoprim + Sulfamethoxazole Bactrim Antibiotic Labetalol + Hydrochlorothiazide Normozide Beta- and alpha-adrenergic “ ” Septra Antibiotic blocker, Thiazide diuretic Trimipramine Surmontil Antidepressant (tricyclic) “ ” Trandate HCT Beta- and alpha-adrenergic blocker, Tripelennamine PBZ Antihistamine Thiazide diuretic Triprolidine Actidil Antihistamine Lisinopril + Hydrochlorothiazide Prinzide Antihypertensive, Thiazide diuretic Triprolidine + Pseudoephedrine Actifed Antihistamine, Decongestant “ ” Zestoretic Antihypertensive, Thiazide diuretic Visblastine Velban Antieoplastic Lovastatin Mevacor Anticholesterol *Non-Steroidal Anti-Inflammatory Drug Maprotiline Ludiomil Antidepressant Meperidine + Promethiazine Mepergan Narcotic analgesic Mesoridazine Serentil Antipsychotic, Tranquilizer Methacycline
Recommended publications
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name

    SPIRONOLACTONE Spironolactone – Oral (Common Brand Name

    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al

    US 201401.00249A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears et al. (43) Pub. Date: Apr. 10, 2014 (54) THERAPEUTIC TREATMENT A63/37 (2006.01) A613 L/45 (2006.01) (71) Applicants: Douglas Sears, Oak Park, CA (US); A613 L/4458 (2006.01) Michael Reilly, Oak Park, CA (US) (52) U.S. Cl. CPC ............... A61K 45/06 (2013.01); A61 K3I/451 (72) Inventors: Douglas Sears, Oak Park, CA (US); (2013.01): A613 L/4458 (2013.01); A61 K Michael Reilly, Oak Park, CA (US) 3 1/137 (2013.01); A61 K31/165 (2013.01) USPC .......................................................... S14/325 (21) Appl. No.: 14/046,528 (57) ABSTRACT (22) Filed: Oct. 4, 2013 This invention discloses a treatment for a patient receiving O O medication to treat an attention deficit disorder Such as Related U.S. Application Data ADHD wherein the treatment results in a loss of appetite and (60) Provisional application No. 61/744,948, filed on Oct. impairment of the patient's attentiveness. The treatment com 9, 2012, now abandoned. bines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases Publication Classification the caloric intake of a patient, which can increase the patients attentiveness. The combination treatment can be given for an (51) Int. Cl. indefinite, including, without limitation, life-long, to allow a A6 IK 45/06 (2006.01) patient to maintain normal caloric intake during treatment for A6 IK3I/65 (2006.01) an attention deficit disorder. 8aasaias: Patent Application Publication Apr. 10, 2014 Sheet 1 of 22 US 2014/010O249 A1 Figure i: improvement in Atiention with increased Caiotic intake 8aakast Patent Application Publication Apr.
  • Prescribing Trends of Antihistamines in the Outpatient Setting in Al-Kharj

    Prescribing Trends of Antihistamines in the Outpatient Setting in Al-Kharj

    Prescribing Trends of Antihistamines in the Outpatient Setting in Al-Kharj Nehad J. Ahmed1*, Menshawy A. Menshawy2 1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia, 2Department of Medicinal chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia Abstract Aim: This study aims to illustrate the prescribing trends of antihistamines in the outpatient setting in Al-Kharj. Materials and Methods: This is a retrospective study that included the evaluation of antihistamines in the outpatient setting in a public hospital in Al-Kharj. The data were collected from the pharmacy-based computer system. Results: The total number of prescriptions that included antihistamines was 799. Most of the prescribed ORIGINAL ARTICLE ARTICLE ORIGINAL antihistamines were first-generation sedating antihistamines (chlorphenamine and diphenhydramine) (66.33%). About 63.20% of the prescribed antihistamines included chlorpheniramine followed by cetirizine (19.27%) and loratadine (14.39%). Conclusion: Antihistamines were prescribed commonly in the outpatient setting mainly first-generation sedating antihistamines. It is recommended to increase the awareness of health- care providers about the efficacy and the side effects of antihistamines and to encourage them to use these agents wisely. Key words: Antihistamines, outpatient, prescribing, trends INTRODUCTION In addition, antihistamines have been classified as sedating antihistamines (first-generation antihistamines) and non- ntihistamines are used in the sedating antihistamines (second-generation antihistamines).[4] management of allergic conditions. Sedating antihistamines include chlorphenamine, clemastine, They are useful for treating the itching hydroxyzine, alimemazine, cyproheptadine, promethazine, A [1] and ketotifen.[4] Non-sedating antihistamines include that results from the release of histamine.
  • Intranasal Rhinitis Agents

    Intranasal Rhinitis Agents

    Intranasal Rhinitis Agents Therapeutic Class Review (TCR) February 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected].
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
  • Cetirizine) – New Drug Approval

    Cetirizine) – New Drug Approval

    Quzyttir™ (cetirizine) – New drug approval • On October 4, 2019, the FDA approved TerSera Therapeutics’ Quzyttir (cetirizine) injection, for the treatment of acute urticaria in adults and children 6 months of age and older. — Quzyttir is not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function. • Quzyttir is the first FDA approved intravenous (IV) formulation of cetirizine. Oral formulations of cetirizine are available generically as prescription as well as well over-the-counter (OTC) (eg, Zyrtec®). — Prescription oral cetirizine is approved for perennial allergic rhinitis and chronic urticaria. — Zyrtec and other OTC products are approved for use to temporarily relieve symptoms due to hay fever or other upper respiratory allergies: runny nose, sneezing, itchy and watery eyes, and itching of the nose or throat. • The efficacy of Quzyttir was established in a randomized, active-controlled, double-blind, single-dose study in 262 adult patients with acute urticaria. Patients were treated with Quzyttir or diphenhydramine injection. The primary efficacy endpoint was the change from baseline in patient-rated pruritus score assessed 2 hours post treatment. The study was non-inferiority design with the pre-specified non- inferiority margin of 0.50 for the difference between treatment groups. — The effectiveness of Quzyttir was demonstrated to be non-inferior to the effectiveness of diphenhydramine. The mean change from baseline in patient-rated pruritus score was -1.61 and -1.50 for Quzyttir and diphenhydramine, respectively (adjusted difference: 0.06; 95% CI: - 0.28, 0.40). • The efficacy of Quzyttir for the treatment of acute urticaria down to 6 months of age is based on extrapolation of the efficacy of Quzyttir in adults with acute urticaria and supported by pharmacokinetic data with oral cetirizine hydrochloride in patients 6 months to 17 years of age.
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Histamine and Antihistamines

    Histamine and Antihistamines

    ACTA FACULTATIS MEDICAE NAISSENSIS UDC: 615.218 DOI: 10.1515/afmnai-2015-0001 Review article Histamine and Antihistamines Nikola Stojković1, Snežana Cekić2, Milica Ristov3, Marko Ristić1, Davor Đukić1, Maša Binić1, Dragan Virijević1 1University of Niš, Faculty of Medicine, PhD student, Serbia 2Institute of Physiology, University of Niš, Faculty of Medicine , Serbia 3Doctor of Medicine SUMMARY In recent years, there has been a steady increase in the prevalence of allergic diseases. Allergic immune response represents a complex network of cellular events involving numerous immune cells and mediators. It represents the interaction of innate and acquired immune response. The key role in the immune cascade is taken by histamine, a natural component of the body, which in the allergic inflammatory response is releasesd by the mast cells and basophils. The aim of this study was to highlight the role of histamine in allergic immunological events, their effect on Th1 and Th2 subpopulation of lymphocytes and the production of the corresponding cytokines, as well as the role of histamine blockers in the treatment of these conditions. Histamine achieves its effect by binding to the four types of its receptors, which are widely distributed in the body. Histamine blockers block a numerous effects of histamine by binding to these receptors. As a highly selective second-generation antihistamine, cetirizine not only achieves its effects by binding to H1 receptors, but also attenuates numerous events during the inflammatory process. Knowledge of the effects
  • Download Article (PDF)

    Download Article (PDF)

    Use of astemizole in a large group practice TIMOTHY J. CRAIG, DO MARK GREENWALD, MD VANESSA KAUFFMANN JILL CRAIG, MS Astemizole was released in 1988. Shortly after the release of astemizole and terfe­ In late 1992, a new warning label was added nadine, it became evident that both were associat­ in response to reports of syncope and death ed with prolonged QT intervals and arrhythmias, from arrhythmia. Records of patients given new mainly torsades de pointes. Because of this associ­ prescriptions for astemizole were reviewed ation, the Food and Drug Administration (FDA) and to assess compliance with the warnings in a the manufacturers provided a warning letter to large multispecialty practice. The indication physicians in 1992.1 For astemizole, the warning was appropriate in 89% of cases. Excessive stated: (1) That arrhythmias have usually occurred doses were used in 4% of cases. Two percent when the dose of 10 mg/d (the recommended dose) of prescriptions were given to patients with was exceeded. Exceeding this dose and the use of contraindications. Only two complications loading doses should be avoided. (2) Serum levels were documented. Despite carrying a drug of astemizole may be elevated by ketoconazole, ery­ warning, astemizole continues to be used thromycin;, and itraconazole. These drugs should inappropriately and is a medicolegal concern. not be used together. (3) Presyncope and syncope Education and drug evaluations can be used may precede fatal arrhythmias and calls for dis­ to enhance compliance and decrease the risk continuing astemizole. (4) The drug should be avoid­ associated with the use of astemizole. ed in patients with significant liver disease.
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone